ACRVHealthcare · BiotechnologyThe 7 Wall Street analysts covering Acrivon Therapeutics, Inc. hold a median 12-month price target of $11 — +461.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Acrivon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (19): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACRV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +461.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Jan 2026 | Piper Sandler | Maintains | Overweight | $6.00 → $8.00 |
| 25 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 16 May 2025 | Jones Trading | Downgrade | Hold | — |
| 15 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
| 26 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 26 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 26 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Jan 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 14 Nov 2024 | BMO Capital | Maintains | Outperform | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright& Co. | Reiterates | Buy | — |
| 16 Sept 2024 | BMO Capital | Reiterates | Outperform | — |
| 16 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 16 Sept 2024 | Ladenburg Thalmann | Upgrade | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2024 | BMO Capital | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACRV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Acrivon Therapeutics, Inc. returned −0.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 74% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 11% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Acrivon Therapeutics, Inc. has a market value of $80.6M and an enterprise value of −$7.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$74.2M.
Free cash flow in the twelve months to 30 June 2026: −$64.1M.
Trailing P/E: −0.9×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 87.00%, paying out 0% of earnings.
Acrivon Therapeutics, Inc. employs 74 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Acrivon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Acrivon Therapeutics, Inc. (ACRV) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock might move higher based on this improved outlook.
Why it matters — A Zacks Rank upgrade signals improved expectations for the company's earnings, which ACRV watchers would consider a favorable development for the stock.
Acrivon Therapeutics' stock reached a key technical support level as its 50-day simple moving average crossed above its 200-day simple moving average, a pattern known as a "golden cross." The development was highlighted in a Zacks Investment Research report.
Why it matters — ACRV watchers may note this technical signal as an indicator of a potential shift in the stock's short-term and long-term momentum trend.
Acrivon Therapeutics, a clinical stage biotechnology company developing precision medicines with its proprietary AP3 platform, announced that its president and CEO, Peter Blume-Jensen, will present at the 2026 Cantor Global Healthcare Conference.
Why it matters — The company leadership's participation at a major healthcare conference provides an opportunity for investors and industry observers to hear directly about Acrivon's progress and strategy.
Acrivon Therapeutics announced the appointment of Michaela Levin, Ph.D., as Chief Business Officer. Levin is an experienced biotechnology executive with a track record in business development, strategic transactions, licensing, and corporate strategy.
Why it matters — ACRV watchers may view the appointment of a senior executive with business-development and deal-making experience as potentially relevant to the company's future strategic and partnership activities.
Zacks Investment Research published an article highlighting Acrivon Therapeutics, Inc. (ACRV) as a strong candidate for momentum investors, posing the question of whether it qualifies as a top momentum stock pick.
Why it matters — ACRV watchers would care because an analyst outlet is drawing attention to the company's momentum characteristics, which may influence investor perception.
The 7 Wall Street analysts covering Acrivon Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Acrivon Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acrivon Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Acrivon Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +461.5% from the last close, and Ticker Nerd's factor model ranks Acrivon Therapeutics, Inc. 68 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Acrivon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $19 over the next 12 months.
Acrivon Therapeutics, Inc. returned -0.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology.
The most recent item we track (Zacks Investment Research, 15 Sept 2026): "What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock". Acrivon Therapeutics, Inc. (ACRV) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock might move higher based on this improved outlook.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.
CEO Dr. Peter Blume-Jensen M.D., Ph.D. · 74 employees · United States · https://acrivon.com
